Corporate Profile

Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.


December  8-11th, 2023
Enalare Therapeutic Presents at the 77th PostGraduate Assembly in Anesthesiology


June 18th, 2023
Poster M31 -Novel ‘Agnostic’ Pharmacologic Approach to Polysubstance Overdose
Poster S119 – Safety and Tolerability of Ascending Doses of ENA-001: A Novel Respiratory Stimulant, for the Intended Management of Pharmacologically-Induced Respiratory Depression

December 6th, 2022
Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman — — Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline
May 2nd, 2022
Herm Cukier, President and Chief Executive Officer, will be presenting at the BioNJ’s Twelfth Annual BioPartnering Conference and Chief Operating Officer, Daniel Motto, will be taking questions after the presentation and meeting with potential investors and strategic partners.
December 28th, 2021
Herm Cukier, President and CEO of Enalare Therapeutics, will provide an update on the Company’s ongoing clinical development program as well as progress on other scientific endeavors. The presentations will be available for viewing on-demand beginning on Jan. 10, 2022 via the H.C. Wainright Bioconnect Conference and the Biotech Showcase 2022 Conference platforms.
May 24th, 2021

BioNJ’s Eleventh Annual BioPartnering Conference

Herm Cukier, President and Chief Executive Officer, presents at the BioNJ’s Eleventh Annual BioPartnering Conference.

February 3rd, 2021
BIO-Europe Spring Conference
Herm Cukier, President and Chief Executive Officer, and Daniel Motto, Chief Operating Officer, will be presenting at the BIO-Europe Spring Conference scheduled for March 22-25, 2021.